Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;5(5):442-53.
doi: 10.1016/j.apsb.2015.07.003. Epub 2015 Aug 24.

Insoluble drug delivery strategies: review of recent advances and business prospects

Sandeep Kalepu  1 , Vijaykumar Nekkanti  2
Affiliations
Review

Insoluble drug delivery strategies: review of recent advances and business prospects

Sandeep Kalepu et al. Acta Pharm Sin B. 2015 Sep.

Abstract

The emerging trends in the combinatorial chemistry and drug design have led to the development of drug candidates with greater lipophilicity, high molecular weight and poor water solubility. Majority of the failures in new drug development have been attributed to poor water solubility of the drug. Issues associated with poor solubility can lead to low bioavailability resulting in suboptimal drug delivery. About 40% of drugs with market approval and nearly 90% of molecules in the discovery pipeline are poorly water-soluble. With the advent of various insoluble drug delivery technologies, the challenge to formulate poorly water soluble drugs could be achieved. Numerous drugs associated with poor solubility and low bioavailabilities have been formulated into successful drug products. Several marketed drugs were reformulated to improve efficacy, safety and patient compliance. In order to gain marketing exclusivity and patent protection for such products, revitalization of poorly soluble drugs using insoluble drug delivery technologies have been successfully adopted by many pharmaceutical companies. This review covers the recent advances in the field of insoluble drug delivery and business prospects.

Keywords: Bioavailability; Cocrystals; Inclusion complexation; Nanoparticles; Proliposomes; Self-emulsifying formulations; Solubility.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Benefits of insoluble drug delivery strategies.
See this image and copyright information in PMC

References

    1. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62:1607–1621. - PubMed
    1. Hodgson J. ADMET—turning chemicals into drugs. Nat Biotechnol. 2001;19:722–726. - PubMed
    1. The 505(b)(2) blog. 2012 approvals. Available from: 〈http://blog.camargopharma.com/index.php/scorecard/2012-approvals〉.
    1. Drews J, Ryser S. Innovation deficit in the pharmaceutical industry. Drug Inf J. 1996;30:97–108.
    1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry, applications covered by section 505(b)(2). Rockville, MD 20857: 1999.